Summary & Overview
HCPCS Q2026: Injection, Radiesse, 0.1 ml
HCPCS Level II code Q2026 denotes a 0.1 ml injection of Radiesse, a calcium hydroxylapatite dermal filler used for soft tissue augmentation and cosmetic volumizing. This code is used to bill for the product unit rather than the administration-only service and matters nationally as the use of injectable aesthetic products continues to grow across outpatient dermatology, plastic surgery, and medical aesthetic settings. Payers assess product-level codes like Q2026 for coverage, coding consistency, and pricing transparency.
Key payers addressed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of what the code represents and where it is typically used, plus an outline of what to expect in deeper sections: payer coverage and policy positions, coding and billing considerations, and clinical context for product use. The publication also summarizes benchmarks and common modifier usage patterns where available. National stakeholders — providers, coders, and payers — can use the information to align coding practice, understand billing implications for dermal filler product units, and locate payer-specific policy references. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code Q2026 describes an injection of Radiesse in a volume of 0.1 ml. This code applies to the administration of a calcium hydroxylapatite dermal filler product used for soft tissue augmentation and cosmetic volumizing procedures.
Service type: Injectable dermal filler administration
Typical site of service: Office-based dermatology or plastic surgery clinic, medical aesthetic practice, or ambulatory surgical center
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult seeking soft tissue augmentation for facial volume loss or contour enhancement using Radiesse (calcium hydroxylapatite) injectable filler. The procedure is performed in an outpatient dermatology, plastic surgery, or medical aesthetic clinic. The patient presents for consultation, medical history and medication review, informed consent, and photographic documentation. Topical anesthetic or local infiltration may be applied. The clinician selects the appropriate Radiesse syringe(s) and administers Q2026 billed per 0.1 mL increment to the targeted areas (e.g., nasolabial folds, marionette lines, cheeks, or jawline) using aseptic technique. Post-injection care includes manual molding as needed, written aftercare instructions, and scheduling follow-up for outcome assessment and potential touch-ups. Adverse events such as bruising, swelling, infection, or vascular compromise are recognized and managed according to standard protocols. Typical site of service: outpatient clinic, ambulatory surgical center, or office-based procedure suite. Service type: injectable dermal filler for soft tissue augmentation.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier | Routine use when no special modifier applies |